T–cell mediated rejection of gene–modified HIV–specific cytotoxic T lymphocytes in HIV–infected patients

@article{Riddell1996TcellMR,
  title={T–cell mediated rejection of gene–modified HIV–specific cytotoxic T lymphocytes in HIV–infected patients},
  author={Stanley R. Riddell and Mark Elliott and Deborah A Lewinsohn and Mark J. Gilbert and L Wilson and Sara A. Manley and Stephen D. Lupton and Robert W. Overell and Thomas C. Reynolds and Lawrence Corey and Philip D. Greenberg},
  journal={Nature Medicine},
  year={1996},
  volume={2},
  pages={216-223}
}
The introduction and expression of genes in somatic cells is an innovative therapy for correcting genetic deficiency diseases and augmenting immune function. A potential obstacle to gene therapy is the elimination of such gene–modified cells by an immune response to novel protein products of the introduced genes. We are conducting an immunotherapy trial in which individuals seropositive for human immunodeficiency virus (HIV) receive CD8+ HIV–specific cytotoxic T cells modified by retroviral… Expand
T-cell gene therapy.
In the past year, a number of human gene therapy trials involving the adoptive transfer of genetically modified T lymphocytes have been reported. These include trials of adenosine deaminase geneExpand
Cellular HIV-1 immune responses in natural infection and after genetic immunization.
TLDR
The cell-mediated immune responses in natural HIV-1 infection and the induction by DNA vaccination in humans are reviewed, showing DNA vaccination to be effective for the induction of both cellular and humoral immune responses as well as for protection from infectious challenge. Expand
Improving T cell therapy for cancer
TLDR
Several new areas of research aimed at improving adoptive T cell therapy for the treatment of cancer are discussed, including the genetic modification of antigen-specific T cells to allow them to perform better in vivo, and conditioning the host to improve in vivo expansion and function of transferred cells. Expand
Genetic modification of T cells for immunotherapy
TLDR
The rationale for genetic modification of T cells, the critical steps involved in gene transfer, and potential advantages and disadvantages of strategies that are now being examined to engineer improved effector T cells for the treatment of human infectious and malignant disease are discussed. Expand
Gene therapy for AIDS.
TLDR
Experimental treatments to augment host anti-HIV1 cytotoxic T lymphocyte responses in an effort to prevent virus spread and, hence, the onset of AIDS hold real promise that require thorough clinical evaluation. Expand
Redirecting T lymphocyte specificity by T cell receptor gene transfer--a new era for immunotherapy.
TLDR
This review discusses basic aspects of retroviral gene transfer, regarding transduction efficacy and transgene expression levels, and considers more recent aspects of T cell specificity engineering, including the possibility of co-transferring coreceptors to create for example functional T helper cells by engrafting CD4(+) T cells with a MHC class I restricted TCR and the CD8 coreceptor and vice versa. Expand
Transfer of Autologous Gene-modified T Cells in HIV-infected Patients with Advanced Immunodeficiency and Drug-resistant Virus.
TLDR
The transfer of gene-modified cells was safe, led to sustained levels of gene marking, and may improve immune competence in HIV-infected patients with advanced disease and multidrug-resistant virus. Expand
Adoptive Immunotherapy of Human Diseases with Antigen-Specific T-Cell Clones
TLDR
The laboratory has been investigating the use of adoptive immunotherapy with antigen-specific T-cell clones to prevent cytomegalovirus infection in allogeneic bone marrow transplant (BMT) recipients; augment immune responses to human immunodeficiency virus (HIV) in HIV-seropositive individuals; and to induce a graft-versus-leukemia (GVL) response inallogeneic BMT recipients. Expand
Genetically modified immunocompetent cells in HIV infection
TLDR
The potential of genetically treated, antigen-specific immunocompetent cells for adoptive autologous immunotherapy of HIV infection and AIDS pathogenesis is discussed. Expand
Lysis of HIV-1-infected cells and inhibition of viral replication by universal receptor T cells.
TLDR
The ability of universal-receptor-bearing CD8+ cells from a seronegative donor to lyse acutely infected cells and inhibit HIV-1 replication in vitro was evaluated and the kinetics of lysis and efficiency of inhibition were comparable to that of naturally occurring HIV- 1-specific CTL clones isolated from infected individuals. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 50 REFERENCES
Principles for adoptive T cell therapy of human viral diseases.
TLDR
The use of recently developed methods to genetically modify antigen-specific T cell clones provides a novel approach to overcome limitations and improve on the safety and efficacy observed in these initial studies, suggesting that more widespread use of adoptive transfer of specific T cells as a therapeutic regimen should be feasible in the near future. Expand
Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses
TLDR
This study has used mice deficient in immunological effector functions in combination with adoptive and passive transfer techniques to define antigen-specific cellular and humoral immune responses that underlie immunological barriers to gene therapy of cystic fibrosis. Expand
Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones.
TLDR
Cytomegalovirus-specific CD8+ cytotoxic T cell (CTL) clones could be isolated from bone marrow donors, propagated in vitro, and adoptively transferred to immunodeficient bone marrow transplant recipients and no toxicity developed and the clones provided persistent reconstitution of CD8+. Expand
Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression
TLDR
It is suggested that active CTL selection of viral variants could contribute to the pathogenesis of AIDS and that clinical progression can occur despite high levels of circulating HIV-1-specific CTLs. Expand
The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells.
TLDR
T cell clones generated and maintained with monoclonal antibody stimulation are rapidly expanded and retain antigen- specific responses after 3 months in culture, suggesting this approach may prove useful for growing large numbers of antigen-specific T cell clones for cellular immunotherapy. Expand
Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation
TLDR
EBV-specific donor-type T-cell lines seem to offer safe and effective therapy for control of EBV-associated lymphoproliferation in patients with EBV reactivation after bone-marrow transplantation. Expand
Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome
TLDR
It is suggested that cellular immunity is involved in the initial control of virus replication in primary HIV-1 infection and a role for CTL in protective immunity to HIV- 1 in vivo is indicated. Expand
In vivo expression and survival of gene-modified T lymphocytes in rhesus monkeys.
TLDR
It is suggested that gene-modified T lymphocytes can survive and circulate for long periods in vivo and can continue to express the introduced genes. Expand
Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy.
TLDR
Approaches for improving recombinant adenoviruses that are based on further crippling the virus to limit expression of nondeleted viral genes are suggested. Expand
Recombinant IL–12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung
TLDR
It is shown that coadministration of interferon–γ (IFN–γ) (or interleukin–12) with the recombinant adenovirus into the airway of C57BL/6 mice diminishes the activation of TH2 cells and formation of neutralizing antibody, allowing for efficient readministration of recombinant virus. Expand
...
1
2
3
4
5
...